A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib

References

• Chen R, Sanchez J, Rosen ST. Clinical management updates in mantle cell lymphoma. Oncology. 2016;30:353–360.
   PubMed Web of Science ®Google Scholar
• Martin P, Ghione P, Dreyling M. Mantle cell lymphoma – current standards of care and future directions. Cancer Treat Rev. 2017;58:51–60.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–1269.
   PubMed Web of Science ®Google Scholar
• Goy A. Mantle cell lymphoma: is it time for a new treatment paradigm? Hematol Oncol Clin North Am. 2016;30:1345–1370.
   PubMed Web of Science ®Google Scholar
• Grover NS, Park SI. Novel targeted agents in Hodgkin and non-Hodgkin lymphoma therapy. Pharmaceuticals. 2015;8:607–636.
   Web of Science ®Google Scholar
• El Halabi L, Ghez D, Ribrag V. Novel targeted therapeutics for mantle cell lymphoma-what's on the horizon? Expert Rev Hematol. 2016;9:271–281.
   PubMed Web of Science ®Google Scholar
• Weniger MA, Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol. 2011;48:214–226.
   PubMed Web of Science ®Google Scholar
• Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ferrero S. European mantle cell lymphoma network. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? Haematologica. 2016;101:104–114.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Hartmann E, Ott G. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23:6364–6369.
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770–1783.
   PubMed Web of Science ®Google Scholar
• Clark AS, Karasic TB, DeMichele A, et al. Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development. JAMA Oncol. 2016;2:253–260.
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012; 119:4597–4607.
   PubMed Web of Science ®Google Scholar
• Marks DL, Olson RL, Fernandez-Zapico ME. Epigenetic control of the tumor microenvironment. Epigenomics. 2016; 8:1671–1687.
   PubMed Web of Science ®Google Scholar
• Li Y, Seto E. Inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:pii:a026831.
   Web of Science ®Google Scholar
• Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood. 2007;110:2667–2673.
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Lembersky D, Son MP, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011;10:1686–1697.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Aust MM, Benson EC, et al. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res. 2014;20:4849–4860.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247–1252.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:1198–1203.
   PubMed Web of Science ®Google Scholar
• Xargay-Torrent S, López-Guerra M, Saborit-Villarroya I, et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Clin Cancer Res. 2011;17:3956–3968.
   PubMed Web of Science ®Google Scholar
• Bhalla S, Balasubramanian S, David K, et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009;15:3354–3365.
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 2005;65:11658–11666.
   PubMed Web of Science ®Google Scholar
• Rao R, Lee P, Fiskus W, et al. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther. 2009;8:1273–1280.
   PubMed Web of Science ®Google Scholar
• Ahrens AK, Chaturvedi NK, Nordgren TM, et al. Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites. Leuk Lymphoma. 2012;53:2269–2278.
   PubMed Web of Science ®Google Scholar
• Hegde GV, Nordgren TM, Munger CM, et al. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling. Int J Cancer. 2012;131:2951–2960.
   PubMed Web of Science ®Google Scholar
• Chaturvedi NK, Rajule RN, Shukla A, et al. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther. 2013;12:2006–2017.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Divakar SKA, Ramana Reddy MV, Cosenza SC, et al. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2016;30:86–93.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541–5552.
   PubMed Web of Science ®Google Scholar
• Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2003;2:151–163.
   PubMed Web of Science ®Google Scholar
• Wang H, Nicolay BN, Chick JM, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017;546:426–430.
   PubMed Web of Science ®Google Scholar
• Wong CC, Qian Y, Yu J. Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. Oncogene. 2017;36:3359–3374.
   PubMed Web of Science ®Google Scholar